非肌层浸润性膀胱癌的新一代测序揭示潜在生物标志物和合理治疗靶点
该研究对105例非肌层浸润性膀胱癌(NMIBC)患者的治疗前肿瘤及配对胚系DNA进行靶向外显子测序,分析突变模式与拷贝数变异。发现TERT启动子突变(73%)和染色质修饰基因改变(69%)普遍存在,ERBB2或FGFR3改变在高分级肿瘤中占57%且互斥,DDR基因改变占30%且与更高突变负荷相关(p<0.001)。ARID1A突变与BCG治疗后复发风险增加相关(HR=3.14,95%CI 1.51-6.51,p=0.002)。
要点
- TERT启动子突变(73%)和染色质修饰基因改变(69%)在NMIBC各分级分期中高发,提示为早期事件。
- 高分级NMIBC中ERBB2或FGFR3改变占57%,呈互斥模式;DDR基因改变占30%,与更高突变负荷相关(p<0.001)。
- ARID1A突变与BCG治疗后复发风险增加相关(HR=3.14,95%CI 1.51-6.51,p=0.002)。
核心结论
- 多数NMIBC肿瘤至少携带一个潜在可干预的基因改变,可作为合理设计的膀胱内或全身治疗试验的靶点。
- DDR基因改变在高分级NMIBC中常见,与突变负荷增加相关,可能对BCG免疫治疗及正在进行的全身免疫检查点抑制剂试验有治疗意义。
- ARID1A突变与BCG治疗后复发风险增加相关,但其是否为BCG反应的预测性生物标志物或NMIBC患者的预后因素需进一步研究。
研究设计与样本
- 前瞻性机构审查委员会批准方案下的靶向外显子测序分析,标本来自105例NMIBC患者的治疗前指标肿瘤及配对胚系DNA。
- 测序在经临床实验室改进修正案认证的临床实验室完成。
主要发现
- TERT启动子突变见于73%的肿瘤,染色质修饰基因改变见于69%,在各分级和分期中均高发。
- 高分级NMIBC肿瘤中57%存在ERBB2或FGFR3改变,呈互斥模式。
- 高分级NMIBC肿瘤中30%(25/82)存在DDR基因改变,与DDR基因完整的肿瘤相比突变负荷更高(p<0.001)。
- ARID1A突变与BCG治疗后复发风险增加相关(HR=3.14,95%CI 1.51-6.51,p=0.002)。
关键数值与推荐
- TERT启动子突变率73%,染色质修饰基因改变率69%。
- 高分级NMIBC中ERBB2或FGFR3改变率57%,DDR基因改变率30%(25/82)。
- ARID1A突变者BCG治疗后复发风险HR=3.14(95%CI 1.51-6.51,p=0.002)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
- ARID1A突变是否为BCG反应的预测性生物标志物或NMIBC的预后因素需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel therapeutic strategies. OBJECTIVE: To identify genetic alterations with potential clinical implications in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: Pretreatment index tumors and matched germline DNA from 105 patients with NMIBC on a prospective Institutional Review Board-approved protocol underwent targeted exon sequencing analysis in a Clinical Laboratory Improvement Amendments-certified clinical laboratory. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Comutation patterns and copy number alterations were compared across stage and grade. Associations between genomic alterations and recurrence after intravesical bacillus Calmette-Guérin (BCG) were estimated using Kaplan-Meier and Cox regression analyses. RESULTS AND LIMITATIONS: TERT promoter mutations (73%) and chromatin-modifying gene alterations (69%) were highly prevalent across grade and stage, suggesting these events occur early in tumorigenesis. ERBB2 or FGFR3 alterations were present in 57% of high-grade NMIBC tumors in a mutually exclusive pattern. DNA damage repair (DDR) gene alterations were seen in 30% (25/82) of high-grade NMIBC tumors, a rate similar to MIBC, and were associated with a higher mutational burden compared with tumors with intact DDR genes (p<0.001). ARID1A mutations were associated with an increased risk of recurrence after BCG (hazard ratio=3.14, 95% confidence interval: 1.51-6.51, p=0.002). CONCLUSIONS: Next-generation sequencing of treatment-naive index NMIBC tumors demonstrated that the majority of NMIBC tumors had at least one potentially actionable alteration that could serve as a target in rationally designed trials of intravesical or systemic therapy. DDR gene alterations were frequent in high-grade NMIBC and were associated with increased mutational load, which may have therapeutic implications for BCG immunotherapy and ongoing trials of systemic checkpoint inhibitors. ARID1A mutations were associated with an increased risk of recurrence after BCG therapy. Whether ARID1A mutations represent a predictive biomarker of BCG response or are prognostic in NMIBC patients warrants further investigation. PATIENT SUMMARY: Analysis of frequently mutated genes in superficial bladder cancer suggests potential targets for personalized treatment and predictors of treatment response, and also may help develop noninvasive tumor detection tests.
引用
- Pietzak EJ, Bagrodia A, Cha EK, et al. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. Eur Urol. 2017. PMID: 28583311. doi:10.1016/j.eururo.2017.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。